版权说明 操作指南
首页 > 成果 > 详情

Lipids, cholesterols, statins and liver cancer: a Mendelian randomization study

认领
导出
Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Liang, Zicheng;Zhang, Zhen;Tan, Xiaoning;Zeng, Puhua
通讯作者:
Zeng, PH
作者机构:
[Liang, Zicheng] Hunan Univ Tradit Chinese Med, Grad Sch, Changsha, Peoples R China.
[Zeng, Puhua; Tan, Xiaoning; Zhang, Zhen] Hunan Acad Tradit Chinese Med, Dept Oncol, Affiliated Hosp, Changsha, Peoples R China.
通讯机构:
[Zeng, PH ] H
Hunan Acad Tradit Chinese Med, Dept Oncol, Affiliated Hosp, Changsha, Peoples R China.
语种:
英文
关键词:
Lipids;Statins;liver cancer;Mendelian randomization;Cholesterols
期刊:
FRONTIERS IN ONCOLOGY
ISSN:
2234-943X
年:
2023
卷:
13
页码:
1251873
基金类别:
This work was supported by the Young Qihuang Scholars Talent Project of National Administration of Traditional Chinese Medicine; the Hunan Provincial Health Commission Traditional Chinese Medicine Shennong Leading Talent Project; the Hunan Province Science and Technology Top Leading Talent Project; the Hunan Provincial Natural Science Foundation (2023JJ40403); and the Hunan Provincial Administration of Traditional Chinese Medicine Research Project (B2023089). Acknowledgments
机构署名:
本校为第一且通讯机构
院系归属:
研究生院
摘要:
Aim: To investigate the causal relationship of serum lipid indicators and lipid-lowering drugs with the risk of liver cancer using Mendelian randomization study. Methods: A two-sample Mendelian randomization (TSMR) study was performed to investigate the causal relationship between serum levels of lipid indicators and liver cancer, including low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), triglycerides (TG), total cholesterol (TC), Apolipoprotein B (ApoB), and Apolipoprotein A1 (ApoA1).Furthermore, inst...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com